Bausch + Lomb (BLCO) Q3 2026 earnings review
Bausch + Lomb lifts its profit plan as eye drops surge
Bausch + Lomb, the maker of contact lenses, surgical implants and eye drops, expanded its profit margins even without an easy comparison to help it. Third-quarter revenue rose 7%, while operating profit before interest, tax and depreciation (excluding one-offs) jumped 34% to $325 million, well above what the company's own prior phasing pointed to. Interim chief executive Thomas J. Appio raised the full-year profit outlook by $65 million, though by our math the new plan leaves profit growing only 4% in the fourth quarter.
| Revenue | $1.375B +7% from a year ago (+8% constant currency) |
|---|---|
| Adjusted EBITDA (excluding acquired R&D) | $325M +34% from a year ago (23.6% margin) |
| Profit per share, excluding one-offs | $0.34 $0.18 a year ago (accounting EPS: $0.09) |
| Full-year Adjusted EBITDA outlook | Raised $65M middle of the range: $1.115B (+25% growth) |
⚖️ Verdict: 🟢 Bullish
The story got better because the third quarter proved that cost savings and higher-margin products are lifting profits against a normal comparison base, not just rebounding from last year's recall. Stronger earnings also pushed operating cash flow up 70%, helping the company chip away at its heavy debt load. One caution: the release unexpectedly named Appio as interim chief executive in place of Brent Saunders and gave no specifics on key clinical trials.
The question now is whether the fourth-quarter slowdown implied by the full-year plan is just cautious forecasting or a sign that margin gains have peaked. If product mix is still improving, fourth-quarter profit will beat the implied $344 million mark; if cost savings are exhausted, margins will flatten out. Fourth-quarter results and the 2027 outlook will settle it.
🐂 Bull Case
Profit Margins Expanded Against a Normal Comparison
Going into the third quarter, the main question was whether Bausch + Lomb's margin gains were just a bounce back from last year's product recall. Interim chief executive Thomas J. Appio pointed to "growth across all three segments and continued expansion in profitability". This quarter settled the debate because third-quarter 2025 already had normal sales, yet profit margins still jumped and the company raised its full-year profit plan by $65 million.
- Adjusted EBITDA (operating profit before interest, tax and depreciation, excluding one-offs): $325 million, up 34% from a year ago
- Adjusted EBITDA margin: 23.6% of sales, up 4.7 percentage points from a year ago by our math
- Cost of making the products, excluding one-offs: 35.3% of sales, down 3.0 percentage points
- Research and development: 6.6% of sales, down 0.8 percentage points, while selling and overhead fell 0.3 points
What to watch: fourth-quarter cost of goods sold as a share of sales. A reading near 35% would confirm that higher-margin eye drops and surgical lenses are permanently lifting profitability.
Higher Profits Lift Cash and Cut Debt Leverage
Bausch + Lomb carries heavy debt, and its planned separation from parent company Bausch Health depends on lowering its debt-to-profit ratio. Operating cash flow jumped 70% from a year ago to $233 million in the third quarter, lifting cash on hand to $515 million from $378 million in June. By our math, trailing twelve-month adjusted EBITDA reached $1.10 billion, up from $1.02 billion last quarter, which directly lowers the leverage ratio.
What to watch: total debt and capital spending in the quarterly filing. If gross debt stayed near $5.1 billion, net debt fell below 4.2 times trailing profit by our math, moving closer to the 2028 target of 3.5 times.
MIEBO Dry-Eye Drops Keep Growing Fast
Pharmaceuticals is Bausch + Lomb's highest-margin division, and its growth rests on MIEBO, a prescription eye drop for dry eye disease. MIEBO sales rose 42% from a year ago to $119 million in the third quarter, up from $91 million in the second quarter. The eye-care group said the drug showed "continued momentum in an expanding category", pushing total Pharmaceuticals revenue up 11% to $367 million.
What to watch: whether management confirms on the call or in the filing that MIEBO has turned profitable on its own, as promised for 2026. Positive contribution from the brand would show the recent Medicare insurance win is adding profit, not just sales volume.
Premium Surgical Lenses Held Their Pace
In the first half of the year, sales of premium intraocular lenses (IOLs), which doctors implant during cataract surgery, looked artificially strong because they were compared against last year's product recall. In the third quarter that easy comparison went away, yet premium IOL revenue still grew about 70% from a year ago, "reinforcing the significant growth opportunity in Surgical", Bausch + Lomb said. Total Surgical sales rose 9% to $234 million.
What to watch: premium IOLs as a share of Surgical revenue in the quarterly presentation or filing. Holding or beating the second quarter's 13% share would prove doctors are choosing pricier lenses beyond mere post-recall restocking.
🐻 Bear Case
The Raised Plan Still Points to a Slow Fourth Quarter
Appio said third-quarter results and a brighter view of the rest of the year drove the higher outlook. Yet the math inside the new plan says almost all of the $65 million profit raise already happened in the third quarter. Three months ago, management indicated third-quarter adjusted EBITDA would be about $268 million; actual profit was $325 million, beating that mark by $57 million.
By our math, subtracting nine-month results from the new full-year middle of the range leaves fourth-quarter revenue growing 5.8% to $1,487 million and adjusted EBITDA rising just 4.2% to $344 million. That implies a fourth-quarter profit margin of 23.1%, down from 23.6% in the third quarter and 23.5% a year ago. Either the forecast is very cautious, or margin gains stall against a strong fourth-quarter comparison.
What to watch: fourth-quarter adjusted EBITDA against the $344 million implied by the full-year outlook. A result only in line with the plan would mean cost savings have already peaked.
One-Off Charges Still Eat Most of the Profit
Bausch + Lomb highlights profit figures that exclude charges it treats as outside normal operations, but those charges happen every quarter. In the third quarter, accounting net income was $32 million, or $0.09 per share, compared with $123 million, or $0.34 per share, excluding one-offs. Over the first nine months of 2026, the company recorded a $53 million accounting net loss against $197 million of adjusted net income.
The $250 million nine-month gap includes $171 million of intangible asset write-downs from past acquisitions, $45 million of restructuring and transformation costs, and $20 million for legal and other matters. Share-based pay added another $109 million to adjusted EBITDA over the nine months, up 28% from a year ago.
What to watch: restructuring and legal charges in the fourth quarter. If these expenses do not shrink as the cost-cutting programme matures, little of the adjusted profit will reach shareholders as accounting earnings.
Risks this quarter didn't answer
Five standing concerns from prior quarters could not be tested from the earnings release alone and await the quarterly filing or conference call.
- Total debt and 2028 refinancing: the release omits the debt table; the quarterly filing will show whether gross debt fell from $5.1 billion.
- Parent company control: Bausch Health still owns about 87% of the shares, and separation remains planned "following the achievement of targeted debt leverage ratios".
- Clinical trial readouts: Bausch + Lomb cited "several potential first-in-class assets reaching clinical and regulatory milestones in the third quarter" without giving Phase 2b dry-eye data or the FDA path for the enVista Beyond lens.
- Tampa factory warning and tariffs: the release gives no update on the June FDA inspection warning in Tampa or the 100% tariff proclamation on patented drugs.
- Consumer eye-care competition: the release does not split consumer sales from contact lenses, leaving vitamin patent expiry and store-brand pressure untested.
👓 Other Themes
Thomas J. Appio Named Interim Chief Executive
The third-quarter release names Thomas J. Appio as chairman and interim chief executive, replacing Brent Saunders, who led Bausch + Lomb through the second quarter. Appio said the company has met its Investor Day goals for four straight quarters and sees "additional opportunities to improve execution, enhance profitability and create even more value over time". The release gives no reason for the leadership change or timeline for a permanent appointment.
💲 Other KPIs
Vision Care, which sells contact lenses and over-the-counter eye drops, grew 5.2% from a year ago (6% excluding currency moves), slowing from 8.4% in the first quarter and 4.1% in the second. Daily silicone hydrogel (SiHy) contact lenses rose 24% and LUMIFY redness-relief drops rose 35%, offsetting currency headwinds of $5 million.
Net interest expense (interest paid on debt minus interest earned on cash) fell 5.1% from $98 million a year ago, bringing the nine-month total to $275 million against $314 million last year. Lower interest costs following recent debt refinancing helped Bausch + Lomb swing to a $32 million third-quarter accounting profit.
Diluted weighted-average shares rose 1.1% from 357.4 million fully diluted shares a year ago and up from 360.2 million in the second quarter. Because Bausch + Lomb posted an accounting profit this quarter, 3.9 million employee stock options and restricted shares entered the diluted count, while the company prioritizes debt reduction over share buybacks.
🔮 Guidance
Raised. The middle of the range moved up $10 million to $5.50 billion, or 7.8% growth (6.1% to 8.0% excluding currency moves, up from 5.8% to 7.7%). Bausch + Lomb lifted its underlying sales plan by $15 million and trimmed currency benefits by $5 million. It is the third raise this year (+$45M, +$20M, +$10M), and by our math leaves 5.8% growth for the fourth quarter.
Raised. Management lifted the range by $65 million to a midpoint of $1,115 million, or 25.1% growth for the year. It is the third raise in three quarters, and the largest by far (+$10M, +$15M, +$65M). By our math, after $771 million in the first nine months, the plan leaves $344 million for the fourth quarter, or 4.2% growth from a year ago.
Cut. The eye-care group lowered its expected full-year currency boost to revenue by $5 million as exchange rates moderated, while keeping the currency effect on adjusted EBITDA at nominal. Because currency helped reported sales by $48 million over the first nine months (including a $6 million drag in the third quarter), the full-year figure implies a $2 million drag in the fourth quarter by our math.
❓ Key Questions
Why Did Brent Saunders Step Down as Chief Executive?
The release names chairman Thomas J. Appio as interim chief executive without explaining Saunders's departure. Investors need to know whether the change alters the Bausch Health separation timeline or the 2028 financial targets.
What Were the Phase 2b Dry-Eye Trial Results?
Management previously said top-line Phase 2b data for its dual-action dry-eye drug would arrive by the end of the third quarter. The release mentions clinical milestones generally but gives no data on this trial or on FDA talks for the enVista Beyond surgical lens.
Why Does the New Plan Imply Flat Fourth-Quarter Margins?
After expanding adjusted EBITDA margin by 4.7 percentage points in the third quarter, the raised full-year outlook implies a 23.1% margin in the fourth quarter by our math, slightly below last year's 23.5%. Management needs to explain whether fourth-quarter costs will rise or if the plan is simply conservative.
Has MIEBO Reached Standalone Profitability Yet?
MIEBO revenue reached $119 million in the quarter, or nearly $480 million annualized. Management previously promised the drug would become a real profit driver in 2026, but avoided confirming whether it was profitable on last quarter's call.